Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884335 | 0.90 | PDE5A (0.45) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL6392444 | 0.89 | PDE5A (0.37) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL6392448 | 0.89 | PDE5A (0.37) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5845631 | 0.87 | PDE5A (0.38) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5845071 | 0.84 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5845866 | 0.81 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5845859 | 0.81 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5847439 | 0.80 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL6220480 | 0.80 | PDE5A (0.36) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5728930 | 0.80 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1CKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115602-B2 | Heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20050065153-A1 | Novel heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1399447-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030139415-A1 | Novel heterocycles 3 | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2002098879-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139415-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885 |
| US-20050065153-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.